DS1, UWWC1-DS1
WISCi005-A
General
Cell Line |
|
hPSCreg name | WISCi005-A |
Cite as: | WISCi005-A (RRID:CVCL_EJ81) |
Alternative name(s) |
DS1, UWWC1-DS1
|
Cell line type | Human induced pluripotent stem cell (hiPSC) |
Similar lines |
|
Last update | 22nd May 2019 |
Notes | The fibroblasts from Coriell turned out to be mosaic (some trisomy, some (10%) normal). Thus, we were able to generate both control and trisomy 21 iPSC lines. |
User feedback | |
Provider |
|
Generator |
University of Wisconsin (WISC)
Contact:
Waisman Center |
Derivation country | United States |
External Databases |
|
BioSamples | SAMEA104242072 |
Cellosaurus | CVCL_EJ81 |
Wikidata | Q54994097 |
General Information |
|
Publications | |
Projects | |
* Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: allowed
Commercial use: allowed
|
Donor Information
General Donor Information |
|
Sex | male |
Age of donor (at collection) | 1-4 |
Phenotype and Disease related information (Donor) |
|
Diseases | A disease was diagnosed.
|
Karyotyping (Donor) |
|
Has the donor karyotype been analysed? |
Yes
Karyotyping method:
G-Banding
|
Other Genotyping (Donor) |
|
Is there genome-wide genotyping or functional data available? |
No
|
Donor Relations |
|
Other cell lines of this donor | |
External Databases (Donor) |
|
BioSamples | SAMEA104242073 |
Ethics
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Was the consent voluntarily given? | Yes |
Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
Please provide contact information of the holder of the original Donor Information Sheet. | Coriell Institute for Medical Research, https://www.coriell.org/ |
Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
If you do not hold the Donor Consent Form, do you know who does? | No |
Alternatives to consent | |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
Does consent expressly prevent the derivation of pluripotent stem cells? | No |
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
How may genetic information associated with the cell line be accessed? | Open Access |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
Name of accrediting authority involved? | Coriell Institute for Medical Research, https://www.coriell.org/ |
Approval number | |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
Name of accrediting authority involved? | Coriell Institute for Medical Research, https://www.coriell.org/ |
Approval number | |
Is there an MTA available for the cell line? | Yes |
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | Addgene |
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No |
hIPSC Derivation
General |
|
Source cell type |
A connective tissue cell which secretes an extracellular matrix rich in collagen and other macromolecules. Flattened and irregular in outline with branching processes; appear fusiform or spindle-shaped.; These cells may be vimentin-positive, fibronectin-positive, fsp1-positive, MMP-1-positive, collagen I-positive, collagen III-positive, and alpha-SMA-negative.
|
Age of donor (at collection) | 1-4 |
Source cell line vendor | Coriell |
Reprogramming method |
|
Vector type | Integrating |
Vector | Virus (Retrovirus) |
Genes | |
Is the used vector excisable? |
No |
Absence of reprogramming vector(s)? |
No |
Reprogramming vectors silenced? | |
Methods used |
Immunostaining
|
Vector free reprogramming |
|
Other |
|
Derived under xeno-free conditions |
No |
Derived under GMP? |
No |
Available as clinical grade? |
No |
Culture Conditions
Surface coating | Matrigel/Geltrex |
Feeder cells |
No |
Passage method | Enzymatically |
Medium | mTeSR™ 1 |
Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Unknown |
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Unknown |
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
POU5F1 (OCT-4) |
Yes |
|
||||
SOX2 |
Yes |
|
||||
SSEA-4 |
Yes |
|
||||
TRA 1-81 |
Yes |
|
Stem cell marker expression, Figure S1, Weick et al., PNAS 2013
Method documentation
Transcriptome Characterisation
Differentiation Potency
In vitro spontaneous differentiation
Marker | Expressed |
AFP |
Yes |
Transcriptome data
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE48611
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE48611
Protocol or reference
In vitro spontaneous differentiation
In vitro directed differentiation
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
47,XY,+21
|
Other Genotyping (Cell Line) |
Login to share your feedback, experiences or results with the research community.